PROXYGEN
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses.
PROXYGEN
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.proxygen.com
Total Employee:
11+
Status:
Active
Contact:
+43 (0)1 226 1030
Email Addresses:
[email protected]
Total Funding:
0
Similar Organizations
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Investors List
Boehringer Ingelheim
Boehringer Ingelheim investment in Grant - Proxygen
Official Site Inspections
http://www.proxygen.com Semrush global rank: 8.56 M Semrush visits lastest month: 289
- Host name: 185.237.67.198
- IP address: 185.237.67.198
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Proxygen"
Proxygen - Crunchbase Company Profile & Funding
Proxygen is reshaping the druggable space. Their company harnesses technology and know-how to exploit this potential, thereby redefining the borders of the druggable target space. They developed rational discovery assays that, …See details»
Proxygen - Hunters
Adam Davenport is Proxygen’s Chief Discovery Officer. A seasoned drug hunter and innovator, he brings over 24 years of hands-on life science and partnership organization experience, having contributed to drug candidates and clinical …See details»
Proxygen - Chronicle
Mar 15, 2024 Proxygen announces formation of Scientific Advisory Board. 15 March 2024 — Proxygen, a leader in the discovery and development of molecular glue degraders, today …See details»
Proxygen Company Profile 2024: Valuation, Funding
Proxygen General Information Description. Developer of a novel drug discovery platform designed to identify glue degraders, small molecules designed to target specific proteins within a cell. The company's platform leverages a deep …See details»
Proxygen - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Proxygen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Monthly Visits 260. Monthly Visits Growth -51.67%. …See details»
Proxygen - Funding, Financials, Valuation & Investors - Crunchbase
Jul 31, 2020 Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses. Search Crunchbase. ... How much …See details»
proxygen.com - Proxygen - Proxygen - Sur.ly
Proxygen.com. Proxygen hunts for molecular glue degraders because they solve the biggest challenge of drug discovery: disease-driving proteins t...See details»
career - Proxygen
For more information, please visit www.proxygen.com. Apply (senior) research scientist – rs24001 + (senior) research scientist – rs24001. Proxygen’s mission is to harness the most innovative, …See details»
Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company
VIENNA, Austria, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced that Fierce Biotech has named it …See details»
Proxygen GmbH (Proxygen GmbH) - 药物管线_专利_临床试验_投 …
Proxygen是一家专注于开发各种临床需求未被满足适应症的分子胶降解剂公司。 其通过精简和充分整合尖端基因组学、蛋白质组学和生化技术，开发了一种高度通用的分子胶降解剂发现引 …See details»
Proxygen GmbH – a new CeMM spin-off company - CeMM
May 18, 2020 Proxygen GmbH will develop therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. Proxygen is focused on …See details»
Proxygen - Updates, News, Events, Signals & Triggers - Crunchbase
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses. Search Crunchbase. Start Free Trial . Chrome …See details»
Proxygen Announces Collaboration and License Agreement with …
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research …See details»
Proxygen GmbH - CeMM
Proxygen GmbH is a startup company with the mission to develop therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. …See details»
Proxygen - Career
Proxygen hunts for molecular glue degraders because they solve the biggest challenge of drug discovery: disease-driving proteins that are difficult – or impossible – to drug. ... The ideal …See details»
Boehringer Ingelheim Collaborates with Proxygen | BI US
Ingelheim, Germany and Vienna, Austria, 7 December 2020 - Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the …See details»
Proxygen inks $2.5B deal with Merck & Co. as collabs stack up
Apr 5, 2023 Proxygen is adding another licensing deal to its repertoire, inking an agreement with Merck & Co. worth more than $2.5 billion. Proxygen’s molecular glue ambitions are continuing …See details»
Proxygen welcomes Adam Davenport as Chief Discovery Officer
Nov 26, 2024 Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the appointment of Adam Davenport as Chief Discovery Officer. A seasoned …See details»
collaboration-proxygen-molecular-glue-degraders - Boehringer …
Dec 7, 2020 Ingelheim, Germany and Vienna, Austria, 7 December 2020 - Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement …See details»